• MAbSilico deploys its AI tools for a fast response in context of pandemic threat

    The use of MAbSilico technologies accelerates the development of antibodies drug candidates against SARS-CoV-2

    In the context of the Covid-19 crisis, MAbSilico deploys its AI technologies to develop faster antibody drug candidates against SARS-CoV-2. Within a group of experts gathered around MAbSilico, the use of two tools is engaged to deliver candidates in a few weeks:

     

    i/ The antibody maturation with MAbMature® method is used to convert anti-SARS-CoV antibodies into anti-SARS-CoV2 antibodies (cf figure, strategy 1). Previously described anti-SARS-Co-V antibodies have already been identified, like the one shown in the figure which inhibits the binding of the spike protein on its receptor ACE2 and subsequent viral entry in its target cells. The comparison between the scFv epitopes on the spike proteins of SARS-CoV and SARS-CoV-2 (this latter one being defined by MAbSilico’s method MAbTope®) shown that the homology between the 2 proteins in the VL interface is too low to predict an actual binding of the scFv on SARS-CoV-2 spike. MAbMature® method is thus applied only to the VH domain which matured CDRs are illustrated in red.

     

    ii/ The antibody selection method MAbSelect® (cf figure, strategy 2) which combines MAbSilico’s similarity-based antibody clustering and affinity prediction methods in the aim of retrieving anti-SARS-Cov2 antibodies from healed patients’ blood samples.

     

    The antibodies drug candidates identified by both methods will be tested in vitro and in vivo.

     

    By engaging these developments, MAbSilico creates a fast track and breakthrough pipeline for antibody drug candidates development to react to the next pandemics.